There are 444 resources available
When is surgery the only best approach for stage I NSCLC and when should we consider systemic adjuvant therapy
Presenter: Hisao Asamura
Session: Controversies in stage I NSCLC
Resources:
Slides
Webcast
Second vote and conclusions/discussion
Presenter: Natasha Leighl
Session: Does liquid biopsy have a role in monitoring adjuvant therapy?
Resources:
Slides
Webcast
Q&A and discussion
Session: Controversies in stage I NSCLC
Resources:
Webcast
Welcome and introduction
Presenter: David Planchard
Session: Clinical Care Options, LLC - TROP-2–targeted ADCs for NSCLC: Integrating a new therapeutic option
Resources:
Webcast
Role of TROP-2 in NSCLC
Presenter: David Planchard
Session: Clinical Care Options, LLC - TROP-2–targeted ADCs for NSCLC: Integrating a new therapeutic option
Resources:
Webcast
Welcome and introduction
Presenter: Zofia Piotrowska
Session: ESMO Colloquium supported by Eli Lilly and Company - Optimising molecular diagnosis and precision therapy in patients with advanced NSCLC harbouring rare oncogenic translocations
Resources:
Webcast
Latest therapeutic advancements in targeting TROP-2 in NSCLC
Presenter: Helena A. Yu
Session: Clinical Care Options, LLC - TROP-2–targeted ADCs for NSCLC: Integrating a new therapeutic option
Resources:
Webcast
Tissue and liquid-based next-generation sequencing diagnostics for patients with advanced NSCLC: Platforms, timings and issues with tissues
Presenter: Antonio Calles Blanco
Session: ESMO Colloquium supported by Eli Lilly and Company - Optimising molecular diagnosis and precision therapy in patients with advanced NSCLC harbouring rare oncogenic translocations
Resources:
Slides
Webcast
Contemplating the future role of targeting TROP-2 in NSCLC
Presenter: Luis Paz-Ares
Session: Clinical Care Options, LLC - TROP-2–targeted ADCs for NSCLC: Integrating a new therapeutic option
Resources:
Webcast
Molecular Reports in advanced NSCLC: How to optimise report structure, molecular tumour board input and actionability
Presenter: Ales Ryska
Session: ESMO Colloquium supported by Eli Lilly and Company - Optimising molecular diagnosis and precision therapy in patients with advanced NSCLC harbouring rare oncogenic translocations
Resources:
Slides
Webcast